en · de · es
melanotan-2-notes.peptides3081.com › Wiki › Peptide Identity And Structural Background — Complete Guide

Peptide Identity And Structural Background — Complete Guide

By Editorial Desk · published 2026-06-08 · last reviewed 2026-07-02 · Wiki

The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-07-02 and is reviewed periodically as new material appears.

Peptide Identity and Structural Background

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Regulation, Literature and Verification

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Synthetic cyclic heptapeptide
Molecular massApproximately 1024 g/molDepends on counter-ion content
AppearanceWhite to off-white powderCommonly supplied as a lyophilised solid
SolubilityFreely soluble in waterAlso dissolves in common aqueous buffers
Typical storage-20 degrees Celsius, desiccatedProtect from light and repeated freeze-thaw

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Handling, Measurement, and Regulatory Context

Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.

Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.

Further detail

== References == Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R., Fletcher, A.A., Macleod, J.J.R. & Noble, E.C. (1922), "The Effect Produced on Diabetes by Extracts of Pancreas", Transactions of the Association of American Physicians, Vol.37, (May 1922), pp. 337–347. Banting, F.G., Best, C.H., Collip, J.B., Macleod, J.J.R. & Noble, E.C. (1922), "The Effect of Pancreatic Extract (Insulin) on Normal Rabbits", The American Journal of Physiology, Vol.62, No.1, (September 1922), pp. 162–176. Biography of James Bertram Collip (1892–1965), Collections U of T (University of Toronto), 2026. Collip, J. Bertram (1916), "Internal Secretions", The Canadian Medical Association Journal, Vol.6, No.12, (December 1916), pp. 1063–1069. Collip, J.B. (1922), "To Prepare Insulin (Collip Process, December 1922)", Collections U of T (University of Toronto). Collip, J.B. (1923), "The Original Method as Used for the Isolation of Insulin in Semipure form for the Treatment of the First Clinical Cases", Proceedings of the American Society of Biological Chemists: Seventeenth Annual Meeting: Toronto, Canada, December 27–29, 1922, (January 1923), pp. xl–xli. Lampard, J. Robert (2008), "James Bertram Collip CBE, MA, PhD, DSc, MD, FRS, FRCPC, FRCS, FACP 1892-1965", pp 311–323 in J. Robert Lampard, Alberta's Medical History: Young and Lusty, and Full of Life, Canada: R. Lampard.

In Brazil, the Aeronautical Accidents Investigation and Prevention Center (CENIPA) was established under the auspices of the Aeronautical Accident Investigation and Prevention Center, a Military Organization of the Brazilian Air Force (FAB). The organization is responsible for the activities of aircraft accident prevention, and investigation of civil and military aviation occurrences. Formed in 1971, and in accordance with international standards, CENIPA represented a new philosophy: investigations are conducted with the sole purpose of promoting the "prevention of aeronautical accidents". In Canada, the Transportation Safety Board of Canada (TSB), is an independent agency responsible for the advancement of transportation safety through the investigation and reporting of accident and incident occurrences in all prevalent Canadian modes of transportation – marine, air, rail and pipeline. In China, the Civil Aviation Administration of China (CAAC) is solely responsible for all air investigations and safety inside the country after the split from the formal CAAC Airlines.

There are no widely accepted functions for the resulting truncated RNA transcripts. However, a study in 1981 found evidence that there was a relationship between the number of abortive transcripts produced and the time until long RNA strands are successfully produced. When RNA polymerase undergoes abortive transcription in the presence of ATP, UTP, and GTP, a complex is formed that has a much lower capacity for abortive recycling and a much higher rate of synthesis of the full-length RNA transcript. A study in 2010 found evidence that these truncated transcripts inhibit termination of RNA synthesis by a RNA hairpin-dependent intrinsic terminator. Oligonucleotide Eukaryotic transcription Bacterial transcription

{\displaystyle RI=5*{25 \over 45}*0.5=} 1.4 The reticulocyte index (RI) should be between 0.5% and 2.5% for a healthy individual. RI < 0.5% with anemia indicates maturation disorder, meaning loss of red blood cells, but also decreased production of reticulocytes (i.e., an inadequate response to correct the anemia) and therefore red blood cells. RI > 2.5% with anemia indicates loss of red blood cells (from causes such as destruction, bleeding, etc.), with an increased compensatory production of reticulocytes to replace the lost red blood cells. Interpretation of these values are not standard and vary based on specific laboratory values and clinical context.

Phospholipase D2 (PLD2) binds PIP2 and localizes with lipid rafts. Increases in cholesterol overcome PIP2 binding and sequester PLD2 into GM1 lipid rafts away from its substrate phosphatidylcholine. Efflux of cholesterol causes PLD2 to translocate to PIP2 domains where it is activated by substrate presentation. Both PIP2 signaling and cholesterol signaling regulate the enzyme. Angiotensin converting enzyme (ACE2) is regulated by PIP2 localization. The ACE2 enzyme is palmitoylated which drives the protein into GM1 lipids. The enzyme also bind to PIP2 which moves it out of the endocytic pathway. The drug hydroxychloroquine blocks ACE2 interaction with PIP2 in multiple cell types shifting its localization. PIP2 binding proteins PH domain PIP2/palmitate proteins GABAA receptor

Sources: en.wikipedia.org

Background from the literature

== Use in healthcare == Medical researchers have studied the use of virtual reality games in healthcare. For example, meta-analyses have demonstrated that virtual reality games could be used for stress management or to improve cognitive and physical functions among elderly post-stroke patients.

=== Alkaline corneal burns === Hitoshi et al. showed that trimebutine can inhibit inflammation in corneal burns caused by alkali. This protective activity is thought to be mediated by high-mobility group box 1-receptor inhibitor, which causes decreased macrophage and neutrophil infiltration.

Santiago Peña Palacios (Latin American Spanish pronunciation: [sanˈtjaɣo ˈpeɲa paˈlasjos]; born 16 November 1978) is a Paraguayan politician and economist who has served as the 52nd president of Paraguay since 2023. Peña served on leadership boards for the Central Bank of Paraguay and Banco Amambay. He taught economics at the Catholic University of Asunción, and has published research papers on monetary policy and finance. Peña is a former member of the Board of Directors of the Central Bank of Paraguay, and former minister of Finance of Paraguay. Peña was a member of the Authentic Radical Liberal Party beginning in 1996, until 2016 when he joined the conservative Colorado Party. He stood as a candidate in the Colorado Party's presidential primary in 2018, where he lost to Mario Abdo Benítez, who went on to be elected president in the 2018 general election. He later won the party's nomination for president in the 2023 general election, in which he ultimately won.

== Diagnosis == There are two types of cystocele. The first is distension. This is thought to be due to the overstretching of the vaginal wall and is most often associated with aging, menopause and vaginal delivery. It can be observed when the rugae are less visible or absent. The second type is displacement. Displacement is the detachment or abnormal elongation of supportive tissue. The initial assessment of cystocele can include a pelvic exam to evaluate leakage of urine when the women is asked to bear down or give a strong cough (Valsalva maneuver), and the anterior vaginal wall measured and evaluated for the appearance of a cystocele. If a woman has difficulty emptying her bladder, the clinician may measure the amount of urine left in the woman's bladder after she urinates called the postvoid residual. This is measured by ultrasound. A voiding cystourethrogram involves taking X-rays of the bladder during urination. This X-ray shows the shape of the bladder and lets the doctor see any problems that might block the normal flow of urine. A urine culture and sensitivity test will assess the presence of a urinary tract infection that may be related to urinary retention. Other tests may be needed to find or rule out problems in other parts of the urinary system. Differential diagnosis will be improved by identifying possible inflammation of the Skene's glands and Bartholin glands.

Sources: en.wikipedia.org

Reference notes

Hertz (1939), operations research scholar known for pioneering the Monte Carlo methods in finance Victor Wouk (1939), pioneer in the development of electric and hybrid vehicles Julius Ashkin (1940), nuclear physicist, brother of Arthur Ashkin '47 Jeremiah Stamler (1940), epidemiologist, expert in the field of preventive cardiology, professor emeritus at Northwestern University Ulrich P. Strauss (1941), chemist at Rutgers University, 1971 Guggenheim Fellow Bruce Wallace (1941), geneticist, professor at Virginia Tech Robert S. Wallerstein (1941), psychoanalyst and former president of the International Psychoanalytical Association and director of the Langley Porter Psychiatric Institute, brother of political scientist Immanuel Wallerstein '51 Kimball Chase Atwood III (1942), geneticist, professor at Columbia University Medical School Leon Davidson (1942), chemical engineer known for his work in the Manhattan Project and the study of Unidentified Flying Objects Karl Koopman (1943), chiropterologist and curator at the American Museum of Natural History Robert G.

An antibody elution is a clinical laboratory diagnostic procedure which removes sensitized antibodies from red blood cells, in order to determine the blood group system antigen the antibody targets. An antibody elution is deemed necessary when antibodies of the immunoglobulin class G (IgG) are found sensitized (bound) to peripheral red cells collected from a blood product transfusion recipient. IgG antibodies are detected using an assay known as the direct antiglobulin test. Antibody elutions are specialized tests used in clinical blood banks. Examples of routine tests include ABO/Rh, antibody screen, antibody identification, and antiglobulin testing. Examples of other specialized tests used in blood banking include: treatment with thiol reagent, monocyte monolayer assay, enzyme treatment, and adsorptions. This procedure aids in the investigation of antibodies that are difficult to identify, distinguishing transfusion reactions, hemolytic disease of the fetus and newborn, and warm autoantibody workups.

==== GABAA receptor positive allosteric modulators ==== Alpidem (Ananxyl; SL800342; SL-800342) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine – discontinued/withdrawn due to toxicity [43] Alprazolam (Xanax) – GABAA receptor positive allosteric modulator and benzodiazepine

Sources: en.wikipedia.org

Frequently asked questions

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

How does it differ from the natural hormone?

It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.

When was Melanotan-2 first described?

Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network